Keywords: GlaxoSmithKline, Human Genome Sciences, Benlysta, Lupus, Advair, Asthma, Europe, USA sales

EU approval for GlaxoSmithKline and Human Genome’s Benlysta; Slowing Advair sales in USA

Article | 15 July 2011

Print This

There was good news for UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Human Genome Sciences (Nasdaq: HGSI) yesterday, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in